<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045006</url>
  </required_header>
  <id_info>
    <org_study_id>MSKCC-01021</org_study_id>
    <secondary_id>CDR0000256306</secondary_id>
    <secondary_id>ATON-0101</secondary_id>
    <secondary_id>NCI-G02-2099</secondary_id>
    <nct_id>NCT00045006</nct_id>
  </id_info>
  <brief_title>Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer</brief_title>
  <official_title>Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid - SAHA (MSK390) in Patients With Advanced Solid Tumors and Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking&#xD;
      the enzymes necessary for cancer cell growth.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in&#xD;
      treating patients who have advanced cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of suberoylanilide hydroxamic acid in patients with&#xD;
           advanced solid tumors or hematologic malignancies.&#xD;
&#xD;
        -  Evaluate the pharmacokinetic profile of this drug in these patients.&#xD;
&#xD;
        -  Determine the effects of this drug on absorption in the fasting and non-fasting states&#xD;
           in these patients.&#xD;
&#xD;
        -  Determine any anti-tumor effects of this drug in these patients.&#xD;
&#xD;
        -  Correlate clinical outcomes with histone acetylation in circulating mononuclear cells&#xD;
           and tumor biopsy samples in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study. Patients are stratified according to disease (solid&#xD;
      tumor vs multiple myeloma or lymphoma vs leukemia or myelodysplastic syndromes).&#xD;
&#xD;
      The initial 15-20 patients (in the solid tumor or multiple myeloma or lymphoma stratum)&#xD;
      receive suberoylanilide hydroxamic acid (SAHA) IV over 2 hours on day 1 of week 0 and then&#xD;
      orally once or twice daily beginning on day 1 of week 1. All remaining patients receive oral&#xD;
      SAHA once or twice daily beginning on day 1 of week 1. Courses repeat every 4 weeks for up to&#xD;
      1 year in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      In each stratum, cohorts of 3-6 patients receive escalating doses of SAHA until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at&#xD;
      least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed monthly for resolution of adverse events.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 114 patients (42 with solid tumors, 36 with lymphoma or&#xD;
      multiple myeloma, and 36 with leukemia or myelodysplastic syndromes) will be accrued for this&#xD;
      study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following diagnoses:&#xD;
&#xD;
               -  Histologically confirmed advanced primary or metastatic solid tumor, including,&#xD;
                  but not limited to, the following:&#xD;
&#xD;
                    -  Androgen-independent prostate cancer&#xD;
&#xD;
                    -  Breast cancer&#xD;
&#xD;
                    -  Ovarian cancer&#xD;
&#xD;
                    -  Head and neck cancer&#xD;
&#xD;
                    -  Non-small cell lung cancer&#xD;
&#xD;
                    -  Bladder cancer&#xD;
&#xD;
                    -  Kidney cancer&#xD;
&#xD;
               -  Diagnosis of lymphoma, multiple myeloma, leukemia, or myelodysplastic syndromes&#xD;
                  (MDS), including, but not limited to, the following:&#xD;
&#xD;
                    -  Intermediate-grade or follicular non-Hodgkin's lymphoma&#xD;
&#xD;
                    -  Hodgkin's lymphoma&#xD;
&#xD;
          -  Patients with lymphoma or multiple myeloma must be ineligible for peripheral blood&#xD;
             stem cell transplantation&#xD;
&#xD;
          -  For patients with solid tumors (except prostate cancer):&#xD;
&#xD;
               -  Disease progression based on development of new lesions or an increase in&#xD;
                  pre-existing lesions&#xD;
&#xD;
               -  Biochemical marker increase must not be sole criterion for disease progression&#xD;
&#xD;
          -  For prostate cancer patients only:&#xD;
&#xD;
               -  Disease progression based on rising prostate-specific antigen (PSA) values,&#xD;
                  transaxial imaging, or radionuclide scans&#xD;
&#xD;
               -  Increase in disease-related symptoms must not be sole manifestation of&#xD;
                  progression&#xD;
&#xD;
               -  Patients receiving an antiandrogen as part of first-line hormonal therapy must&#xD;
                  show disease progression off of the antiandrogen prior to study&#xD;
&#xD;
               -  Biochemical progression (at least 25% increase over range of values) defined as 1&#xD;
                  of the following:&#xD;
&#xD;
                    -  Rising PSA documented by at least 3 consecutive measurements obtained at&#xD;
                       least 1 week apart&#xD;
&#xD;
                    -  Rising PSA documented by at least 2 consecutive measurements obtained more&#xD;
                       than 1 month apart&#xD;
&#xD;
               -  PSA at least 4 ng/mL&#xD;
&#xD;
                    -  Testosterone no greater than 50 ng/mL&#xD;
&#xD;
                    -  If no prior orchiectomy, must maintain castrate levels of testosterone&#xD;
&#xD;
          -  Disease must be refractory to standard therapy or for which no curative therapy exists&#xD;
&#xD;
          -  No active CNS or epidural tumors&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified NOTE: A new classification scheme for adult non-Hodgkin's lymphoma&#xD;
                  has been adopted by PDQ. The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma&#xD;
                  will replace the former terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade&#xD;
                  lymphoma. However, this protocol uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 (patients with solid tumors)&#xD;
&#xD;
          -  Platelet count greater than 25,000/mm^3 (patients with hematologic malignancy)&#xD;
&#xD;
          -  Absolute neutrophil count at least 500/mm^3 (patients with hematologic malignancy)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 3 times ULN&#xD;
&#xD;
          -  PT no greater than 15 seconds&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No severe debilitating pulmonary disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No infection requiring IV antibiotics&#xD;
&#xD;
          -  No other severe medical problems that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior ketoconazole&#xD;
&#xD;
          -  At least 2 weeks since prior steroids for patients with lymphoma&#xD;
&#xD;
          -  Concurrent gonadotropin-releasing hormone analogs or diethylstilbestrol to maintain&#xD;
             castrate levels of testosterone allowed for prostate cancer patients&#xD;
&#xD;
          -  No concurrent ketoconazole&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy to sole measurable lesion&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 4 weeks since prior palliative therapy for solid tumor patients with&#xD;
             progressive metastatic disease (if present)&#xD;
&#xD;
          -  At least 4 weeks since prior investigational anticancer therapeutic drugs&#xD;
&#xD;
          -  At least 2 weeks since prior conventional cytotoxic therapy for patients with leukemia&#xD;
             or MDS&#xD;
&#xD;
          -  At least 4 weeks since prior investigational therapy for patients with leukemia or MDS&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William K. Kelly, DO</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2003</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>ovarian stromal cancer</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III ovarian germ cell tumor</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>stage III oropharyngeal cancer</keyword>
  <keyword>stage IV oropharyngeal cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>stage III basal cell carcinoma of the lip</keyword>
  <keyword>stage IV basal cell carcinoma of the lip</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage III mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage III adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage III verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>male breast cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

